Curated News
By: NewsRamp Editorial Staff
October 19, 2026
TransCode's TTX-MC138 Poster to Debut at ESMO 2026
TLDR
- TransCode Therapeutics will present Phase 1a data on TTX-MC138 at ESMO 2026, showcasing a first-in-class miR-10b targeting approach for metastatic cancers.
- TTX-MC138 targets miR-10b, a microRNA linked to metastasis, and its Phase 1a trial update will be presented at ESMO 2026 in Madrid.
- TransCode Therapeutics advances TTX-MC138, a novel RNA therapy for aggressive cancers, offering hope for better outcomes in metastatic disease.
- TransCode Therapeutics will share early clinical results for TTX-MC138, an RNA-based drug aimed at microRNA-10b, at ESMO 2026 in Madrid.
Impact - Why it Matters
The upcoming ESMO presentation underscores the progress of TTX-MC138, a first-in-class RNA therapeutic targeting miR-10b, a key driver of metastasis. Positive Phase 1a data could validate TransCode's approach to treating metastatic cancers, potentially attracting investment and partnerships. For patients with advanced solid tumors, this represents a novel strategy that may address unmet needs. The news also highlights the role of communications platforms like NetworkNewsWire in disseminating critical developments to investors and the public.
Summary
TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage immuno-oncology and RNA therapeutics company, announced that a poster featuring its lead candidate TTX-MC138 will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors. TTX-MC138 is designed to target miR-10b, a microRNA associated with metastatic disease progression.
TransCode focuses on high-risk and advanced cancers, and TTX-MC138 is its lead therapeutic candidate aimed at metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of first-in-class candidates designed to mobilize the immune system against cancer cells. For full details, visit the full press release. Investors can find the latest news and updates in the company’s newsroom at https://nnw.fm/RNAZ.
The announcement was distributed through NetworkNewsWire (NNW), a specialized communications platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. This broad reach helps companies like TransCode gain visibility among investors and the public.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode's TTX-MC138 Poster to Debut at ESMO 2026
